Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.57 |
| ▸ | DPP4 | P27487 | 5/20 | 0.57 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850058 | 0.91 | DPP7 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL29376792 | 0.91 | DPP7 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL8497101 | 0.90 | DPP7 (0.57) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL30517415 | 0.88 | DPP7 (0.55) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL30555003 | 0.88 | DPP7 (0.55) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL29399358 | 0.87 | DPP7 (0.54) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL30868624 | 0.87 | DPP7 (0.54) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL29548213 | 0.87 | DPP7 (0.54) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL1556756 | 0.87 | DPP7 (0.54) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL17696520 | 0.86 | NOD1 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-01-27 | — | — | US | disclosed |
| CN-112165953-B | Compounds useful as apelin receptor antagonists | 剑桥企业有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240279280-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-22 | — | — | US | disclosed |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | APLNR, NPBWR1, AP3B1 | DPP7 520/4885DPP9 678/4885DPP8 376/4885 |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | APLNR, GIPR, GRPR | DPP7 377/4885DPP9 504/4885DPP8 422/4885 |
| US-20240279280-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | APLNR, GIPR, GRPR | DPP7 377/4885DPP9 504/4885DPP8 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.